Skip to Content

Rilonacept Regeneron

Previous name: Arcalyst
Active Substance: rilonacept
Common Name: rilonacept
ATC Code: L04AC08
Marketing Authorisation Holder: Regeneron UK Limited
Active Substance: rilonacept
Status: Withdrawn
Authorisation Date: 2009-10-23
Therapeutic Area: Cryopyrin-associated Periodic Syndromes
Pharmacotherapeutic Group: Immunosuppressants

Therapeutic Indication

Rilonacept Regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children aged 12 years and older.

The marketing authorisation for Rilonacept Regeneron has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.